Bioadaptives Stock Price, News & Analysis

BioAdaptives, Inc. (OTCMkts: BDPT) plans to spin off its Livestock Impact Division as a wholly-owned subsidiary, focusing on natural supplements for performance animals and pets. The new entity aims to expand globally into botanical drugs for veterinary and human use, leveraging a rapidly growing market valued at USD 163 million in 2021 and projected to reach USD 3.221 billion by 2030, with a CAGR of 39% from 2022-2030. CEO Edward Jacobs highlighted the recent addition of industry experts Dr. Yaguang Liu and Dr. David Allen to the Board of Directors, enhancing the company's ability to navigate the global botanical drug opportunity. BioAdaptives specializes in natural plant- and algal-based health products, with a diverse existing product line for both humans and animals, although its claims are not FDA approved.

BioAdaptives, Inc. (OTCMkts: BDPT) announced a non-exclusive licensing agreement with LY Research Corporation to market a patented resveratrol product for both animals and humans. The agreement aims to leverage the health benefits of resveratrol, known for its anti-inflammatory and antioxidant properties. CEO Edward Jacobs expressed optimism about expanding the product line within their Livestock Impact Division, targeting the veterinary supplement market projected to grow from $6.85 billion in 2020 to $13.76 billion by 2031 at a CAGR of 6.5%. Involvement from notable figures like David Allen, PhD, highlights potential therapeutic benefits of resveratrol, particularly in managing equine joint issues. While the company emphasizes the promising nature of its products, it also notes that statements have not been FDA approved and are not intended to diagnose or treat diseases.

BioAdaptives, Inc. (OTCMkts: BDPT) has announced the appointment of David Allen, PhD, to its Board of Directors. Edward Jacobs, M.D., CEO, expressed enthusiasm for Dr. Allen's extensive experience in developing wellness products globally, which is expected to benefit the company's expansion into new markets. Dr. Allen's background includes leadership roles in various wellness organizations, including the American Botanical Drug Association, and involvement in FDA pathways for botanical drug development. BioAdaptives focuses on natural health products for both humans and animals, with current offerings aimed at pain relief, immune support, and overall wellness. The company aims to introduce new products targeting cognitive health and emotional wellness soon. BioAdaptives currently has over 13,000 shareholders.

BioAdaptives, Inc. (OTCMkts: BDPT) has entered an exclusive marketing agreement with Flying C Bar Ranch (FCBR) Therapy Division to promote its LiveStock Impact line of performance supplements for equines and pets. This partnership builds on a five-year collaboration, enhancing marketing efforts due to FCBR's deep understanding of the products and established consumer relationships. The pet supplements market, valued at $1.9 billion in 2021, is projected to grow at a CAGR of 5.9% from 2022 to 2030. The agreement aims to expand product offerings and leverage FCBR's reputation in equine sports, with potential for developing new botanical drugs. BioAdaptives manufactures natural supplements focused on health improvement and performance enhancement for both animals and humans.